BUZZ — Iovance hits two — year high after raising annual revenue forecast
* Shares of Iovance Biotherapeutics rise 27.5% to $14, their highest level in more than two years * Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln * "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue